![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/23/2935084/0/en/Tempest-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/06/20/2901630/0/en/Tempest-Unveils-New-Survival-Data-for-Amezalpat-TPST-1120-in-Randomized-First-Line-HCC-Study-Demonstrating-a-Six-Month-Improvement-over-Control-Arm.html
https://www.globenewswire.com/news-release/2024/06/18/2900863/0/en/Tempest-to-Report-New-Data-from-Global-Randomized-Combination-Study-of-Amezalpat-TPST-1120-in-First-Line-Hepatocellular-Carcinoma.html
https://www.globenewswire.com/news-release/2024/06/07/2895236/0/en/Tempest-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/05/21/2885529/0/en/Tempest-to-Participate-in-Upcoming-Investor-Conferences.html
https://www.globenewswire.com/news-release/2024/05/09/2879243/0/en/Tempest-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/04/26/2870731/0/en/Tempest-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/04/09/2859912/0/en/Tempest-Reports-New-Preclinical-Data-for-TPST-1120-in-RCC-at-the-AACR-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/04/04/2857718/0/en/Tempest-Announces-Publication-of-Positive-Data-from-Phase-1-Trial-of-TPST-1120-in-Patients-with-Advanced-Solid-Tumors-in-Journal-of-Cancer-Research-Communications.html
https://www.globenewswire.com/news-release/2024/03/19/2848979/0/en/Tempest-Reports-Year-End-2023-Financial-Results-and-Provides-Business-Update.html